Brief: Abbisko Cayman Says Positive Top-Line Results From Phase 3 Maneuver Study Of Pimicotinib In TGCT Patients
12/11/2024 01:23
Nov 12 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 MANEUVER
STUDY OF
PIMICOTINIB IN TGCT PATIENTS
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly